Dose-Response Relationship, Immunologic
                             
                            
                            
                                
                            
                            
                                
                            
                            
                            
                                
                                    
                                            
	"Dose-Response Relationship, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, 
	MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, 
	which enables searching at various levels of specificity.
	
	
		
			
			
				A specific immune response elicited by a specific dose of an immunologically active substance or cell in an organism, tissue, or cell.
    
			
			
				
				
					
						| Descriptor ID | D004306 | 
					
						| MeSH Number(s) | G12.300 | 
					
						| Concept/Terms | Dose-Response Relationship, ImmunologicDose-Response Relationship, ImmunologicDose Response Relationship, ImmunologicImmunologic Dose-Response RelationshipDose-Response Relationships, ImmunologicImmunologic Dose Response RelationshipImmunologic Dose-Response RelationshipsRelationships, Immunologic Dose-ResponseRelationship, Immunologic Dose-ResponseRelationship, Immunologic Dose Response
 | 
					
				
			 
			
				Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Immunologic".
				
			 
			
			
				Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Immunologic".
				
			 
		 
	 
 
                                        
                                            
	
	
		
			
			
					
				This graph shows the total number of publications written about "Dose-Response Relationship, Immunologic" by people in this website by year, and whether "Dose-Response Relationship, Immunologic" was a major or minor topic of these publications. 
				
					 
                    To see the data from this visualization as text, 
click here. 
                
		            | Year | Major Topic | Minor Topic | Total | 
|---|
| 1996 | 0 | 5 | 5 | 
| 1997 | 0 | 1 | 1 | 
| 1999 | 0 | 3 | 3 | 
| 2000 | 0 | 3 | 3 | 
| 2001 | 0 | 3 | 3 | 
| 2002 | 0 | 3 | 3 | 
| 2003 | 0 | 5 | 5 | 
| 2004 | 0 | 2 | 2 | 
| 2005 | 0 | 4 | 4 | 
| 2006 | 0 | 6 | 6 | 
| 2007 | 0 | 3 | 3 | 
| 2008 | 0 | 5 | 5 | 
| 2009 | 0 | 1 | 1 | 
| 2010 | 0 | 1 | 1 | 
| 2011 | 0 | 3 | 3 | 
| 2012 | 0 | 1 | 1 | 
| 2013 | 0 | 2 | 2 | 
| 2015 | 0 | 2 | 2 | 
| 2016 | 1 | 4 | 5 | 
| 2017 | 0 | 2 | 2 | 
| 2018 | 0 | 2 | 2 | 
| 2020 | 0 | 2 | 2 | 
| 2021 | 0 | 1 | 1 | 
                    To return to the timeline, 
click here.
                 
			 	
			
			
			
			
				Below are the most recent publications written about "Dose-Response Relationship, Immunologic" by people in Profiles.
						
					
								- 
								Progressive, refractory macrophage activation syndrome as the initial presentation of anti-MDA5 antibody positive juvenile dermatomyositis: a case report and literature review. Pediatr Rheumatol Online J. 2022 Feb 22; 20(1):16. 
- 
								Differences in rituximab use between pediatric rheumatologists and nephrologists for the treatment of refractory lupus nephritis and renal flare in childhood-onset SLE. Pediatr Rheumatol Online J. 2021 Aug 30; 19(1):137. 
- 
								Asprosin-neutralizing antibodies as a treatment for metabolic syndrome. Elife. 2021 04 27; 10. 
- 
								Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020 10; 26(10):1569-1575. 
- 
								Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2021 02; 21(2):275-285. 
- 
								Characterization of novel conformation-selective a-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease. Neurobiol Dis. 2020 03; 136:104712. 
- 
								Efficacy of the Bartha-K61 vaccine and a gE-/gI-/TK- prototype vaccine against variant porcine pseudorabies virus (vPRV) in piglets with sublethal challenge of vPRV. Res Vet Sci. 2020 Feb; 128:16-23. 
- 
								A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med. 2019 12 10; 38(28):5299-5316. 
- 
								AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018 Nov 22; 379(21):1991-2001. 
- 
								A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus. J Infect Dis. 2018 11 05; 218(12):1883-1889.